Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AI, assessor, Chemoimmunotherapy, CISSP, cluster, clustered, College, commensurate, contrast, Counsel, CTCL, CY, Daratumumab, DLCBL, druggable, Flatiron, grantee, hallmark, Head, incident, induction, influenza, leukocyte, logo, mantle, MCL, modality, MT, multidisciplinary, obinutuzumab, oHuman, omission, opponent, payout, peak, pertinent, phishing, PISSC, poster, relocation, Sigma, sit, sizable, slowdown, Steering, sublease, suboptimal, Syncytial, trusted, trustworthy, undergraduate, unparalleled, unrecoverable, VRd, Wisconsin, worsening
Removed:
Absent, Adapter, adjusting, affinity, AG, ALCYONE, analytic, Analyzer, annotate, annotated, answer, anticorruption, approached, attended, avoiding, backlog, biggest, Biotech, Black, blended, Bortezomib, card, characterization, classic, closely, cohort, collected, combat, combined, compliant, concordance, constantly, constituting, convert, cornerstone, Council, CR, currency, cutoff, cytokine, cytotoxic, cytotoxicity, Dana, Darzalex, declined, detectable, DFCI, differentiator, digit, discontinuing, distract, divided, downstream, easy, EFS, ELISPOT, endure, enjoined, EP, epidemic, EUA, evaluable, expiring, explore, exponentially, Farber, filter, Finally, heavy, hidden, HR, hybridization, ideal, immunecode, immunological, immunoSEQ, immunospot, Importantly, incubate, induced, infecting, insight, instability, Institute, interaction, Invivoscribe, iterative, Janssen, Japan, jurisdictional, Keygene, labor, largest, leader, licensee, locally, loci, longest, lung, malignancy, malignant, marker, Melphalan, mentoring, modern, modifying, multicenter, narrow, negotiating, neutralization, neutralize, newest, NPA, NV, observational, observe, obstacle, odyssey, orientation, origin, outbreak, owner, paradigm, paramount, Pat, peer, penetrate, pioneered, positioned, potency, PPA, pre, Prednisone, preparing, privilege, programming, prototype, proven, purview, quantitation, query, RBD, reactivity, realizing, referencing, region, registry, release, renal, repeatedly, reproducibility, reveal, revealed, RNA, Roche, running, screen, selected, separated, served, simplifying, solved, sooner, sourcing, spike, staffing, standardized, stratification, strongly, surrogate, symptom, symptomatic, synergistic, synthesized, tailoring, thousand, threshold, titrating, transplant, transportation, Trimer, TruTCR, UK, unbiased, unrest, untimely, user, vaccine, viral, virtual, visualization, VMP
Filing tables
Filing exhibits
Related press release
Associated ADPT transcripts
ADPT similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)
Registration Statement (Form S-8 No. 333-269767) pertaining to the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and the Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan and
(2)
Registration Statement (Form S-8 No. 333-232495) pertaining to the Sequenta Inc., 2008 Stock Plan, the Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan, the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and the Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan;
of our reports dated February 29, 2024, with respect to the consolidated financial statements of Adaptive Biotechnologies Corporation, and the effectiveness of internal control over financial reporting of Adaptive Biotechnologies Corporation, included in this Annual Report (Form 10-K) for the year ended December 31, 2023.
/s/ Ernst & Young LLP
Seattle, Washington
February 29, 2024